Posted by Michael Wonder on 27 Apr 2026
AbbVie submits regulatory application to FDA for Skyrizi (risankizumab-rzaa) subcutaneous induction for adults with moderately to severely active Crohn's disease
27 April 2026 - Submission supported by data from Phase 3 pivotal AFFIRM study.
AbbVie today announced that it has submitted an application to the US FDA seeking approval for Skyrizi (risankizumab-rzaa) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn's disease.
